INTRODUCTION

Cervical cancer (CC) is the third most common leading cause of cancer death among females in developing countries. More than 274,000 individuals die each year. In China, approximately 98,900 new cases were diagnosed in 2015, which accounted for 18.7% of the global incidence. Additionally, 30% of patients were <44 years old. Reportedly, the 5-year survival rates for locally advanced CC vary as follows: 58% for stage IIB, 35% for IIIA, 32% for IIIB and 16% for stage IVA. Therefore, it is urgent to identify novel molecular markers to improve the early diagnosis rate of CC and to develop an effective treatment strategy.

Inositol polyphosphate-1-phosphatase (INPP1) is an enzyme that dephosphorylates free polyphosphorylated inositols, key molecules involved in phosphatidylinositol signalling pathways. Presently, it has been reported that INPP1 is up-regulated in human colorectal cancer. Daniel et al. also found that INPP1 is highly expressed in aggressive melanoma, prostate, ovarian and breast cancer cells to promote migration and invasion; this finding suggests that INPP1 may function as an oncogene. However, the role of INPP1 in CC is still unclear.

MicroRNAs (miRNAs) are small non-coding RNAs that can bind to the 3' UTR of target mRNAs, resulting in translational repression or degradation to regulate a wide range of physiological and pathological processes. Recent findings demonstrate that miRNA also binds to the 3' UTR of mRNAs to raise the expression levels of their target genes. Furthermore, accumulating evidence has indicated that the miRNA profiles were differentially expressed in human cancerous tissues and adjacent normal tissues. The dysregulated miRNAs may function as tumour suppressors or oncogenes, which present diagnostic and prognostic values in clinical applications. miR-27a was found to be up-regulated and to promote malignancy in CC tissues compared to that in adjacent normal tissues by RT-qPCR. Inositol polyphosphate-1-phosphatase overexpression promoted and INPP1 knock-down suppressed cell viability, cellular migration/invasion and EMT in CC cells. To explore the mechanism of dysregulation, INPP1 was predicted to be a target of miR-27a, and a pmiRGLO dual-luciferase reporter assay showed that miR-27a bound to the 3' UTR of INPP1. RT-qPCR revealed that miR-27a was also up-regulated and had a positive correlation with INPP1 expression in CC tissues. Furthermore, shR-INPP1 could favour the malignant phenotype reversion induced by miR-27a, suggesting that miR-27a up-regulates INPP1 to promote tumorigenic activities. Altogether, our findings show that the up-regulation of INPP1 by miR-27a contributes to tumorigenic activities and may provide a potential biomarker for CC.

KEYWORDS
cervical cancer (CC), INPP1, miR-27a
in non–small‐cell lung cancer, breast cancer, prostate cancer, liver cancer, CC, etc. In this report, we show that INPP1 is up‐regulated in CC tissues compared with the levels in adjacent normal tissues. Inositol poly‐phosphate‐1‐phosphatase promoted cell proliferation and invasion/migration. miR‐27a bound to the 3′ UTR of INPP1 to increase the expression in CC cells. Rescue experiments indicated that INPP1 is a functional target gene of miR‐27a. Overall, our present work proved that miR‐27a promotes INPP1 expression to contribute to the malignant properties of CC cells, which may serve as biomarkers for the diagnosis of CC.

2 | MATERIALS AND METHODS

2.1 | Human cervical cancer tissue specimens and cell lines

Twenty human CC tissues and adjacent normal tissues were obtained from the Tianjin Central Hospital of Obstetrics and Gynecology, China. Written informed consent was obtained from each patient, and ethics approval for this work was granted by the Ethics Committee of Tianjin Central Hospital of Obstetrics and Gynecology. The cervical samples were verified and classified by pathologists. The human CC cell lines HeLa and SiHa were cultured in RPMI 1640 medium containing 10% heat-inactivated foetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin.

C33A was cultured in DMEM. All cells were incubated in a humidified atmosphere at 37°C with 5% CO₂.

2.2 | Plasmid construction

The miR-27a precursor was cloned from the genome by PCR and was inserted into the pcDNA3 vector by BamH1/EcoRI digestion. Small interfering RNAs against miR-27a (ASO-miR-27a) were synthesized by GenePharma. The wild-type INPP1 3′ UTR including the target site of miR-27a and a mutant containing a mutation in the miR-27a target site were cloned into the pmiRGLO vector (Promega) using PmeI/XbaI digestion. The INPP1 cDNA was cloned from the mRNA by PCR and was inserted into the pcDNA3-Flag vector using BamH1/XbaI digestion, thus generating pcDNA3-Flag/INPP1 (pINPP1). Two strands were annealed and cloned into the vector pSilencer 2.1-U6 neo (Ambion) using BamH1/XbaI digestion to construct the INPP1 shRNA expression plasmid pSilencer/shR-INPP1 (pshR-INPP1). The sequences of the primers used are listed in Table 1.

### Table 1

| Name | Sequence (5′-3′) |
|------|-----------------|
| pri-miR-27a-5'-XhoI | CGGGGATCCACCTGAGCTCTGCCCCG |
| pri-miR-27a-AS-EcoRI | CGGAATTCGAGGATGGCAGCCAGAC |
| ASO-miR-27a | GCGGAACCUUGGACUGUGAA |
| ASO-NC | CAGACUCUUUGGUGAUAGACAA |
| miR-27a-RT | GTCGTATCCAGTGAGGTCAGGATAGTCCACTGAGATCGAGACG |
| miR-27a-Fwd | TGGCTGTTCAAGTGGCTAAG |
| U6-RT | GTCGTATCCAGTGAGGTCAGGATAGTCCACTGAGATCGAGACG |
| U6-Fwd | TGGCTGTTCAAGTGGCTAAG |

2.3 | RNA extraction and real-time PCR

RNA from patient tissues was extracted by the miRcute miRNA Isolation Kit (Tiangen Biotech) according to the manufacturer’s instructions. TRIzol reagent (Invitrogen) was used to isolate the total RNA from CC cells. Then, reverse transcriptase-polymerase chain reaction (RT-PCR) methods were used for cDNA synthesis with
Moloney murine leukaemia virus (M-MLV) reverse transcriptase (Promega). A SYBR Premix Ex Taq II Kit (Takara) was used for qPCR in a Thermal Cycler Dice™ Real Time System III (TaKaRa). β-Actin or U6 snRNA was used as an internal control. The relative transcript-level fold-change was calculated using the $2^{-\Delta\Delta Ct}$ method.\(^{26}\)

2.4 | Western blot analysis

The protein samples were obtained by using radioimmunoprecipitation assay (RIPA) lysis buffer to lyse the cells for almost 30 minutes at 4°C. The primary antibodies used in the Western blot assay are as follows: (a) rabbit anti-GAPDH (Tianjin Saier Biotech; 1:2000), (b) rabbit anti-INPP1 (Abcam, 1:1000), (c) rabbit anti-E-cadherin (Tianjin Saier Biotech; 1:1000) and (d) rabbit anti-vimentin (Tianjin Saier Biotech; 1:1000). Anti-rabbit IgG-HRP secondary antibodies were also used for Western blotting. Lab Works™ Image Acquisition and Analysis Software (UVP) was used for the quantification of the bands in the form of grey intensities.

2.5 | Luciferase reporter assays

HeLa (4 × 10^4 cells/well) or C33A (5 × 10^4 cells/well) cells were inoculated into 48-well plates. After 16 hours, 0.5 µg of pri-miR-27a, ASO-miR-27a or the controls and 0.5 µg of reporter vector pmiR-GLO-INPP1-3′ UTR/mut were cotransfected using Lipofectamine 2000 reagent (Invitrogen). After 48 hours of transfection, the cells were lysed by the Dual-Luciferase Reporter Assay System (Promega).

2.6 | Cell viability assay and colony formation assay

HeLa (8 × 10^4 cells/well), SiHa (1 × 10^5 cells/well) and C33A (1 × 10^5 cells/well) cells were inoculated into 24-well plates. After 16-18 hours, 1 µg of the plasmids was transfected using Lipofectamine 2000 reagent (Invitrogen). After 24 hours of transfection, the cells were digested with 0.01% trypsin and counted by a haemocytometer. HeLa (2 × 10^5 cells/well), SiHa (3 × 10^5 cells/well) and C33A (5 × 10^5 cells/well) cells were inoculated into 96-well plates to detect the cell viabilities by an MTT assay. HeLa (2 × 10^2 cells/well), SiHa (3 × 10^2 cells/well) and C33A (3 × 10^2 cells/well) cells were seeded into 12-well plates to detect the colony formation rate. The details were described previously.\(^{27}\)

2.7 | Wound healing and cell invasion assays

For the wound healing assay, the movement of cells into the scraped area was measured to determine cell migration at 0, 48 and 72 hours as described by Ref. 25 For the invasion assays, the cells at the lower surface of the filter were counted as described previously.\(^{28}\)

2.8 | Statistical analyses

The significant differences between the sample means obtained from the three independent experiments were analysed using two-tailed Student’s t tests. Multiple group comparisons were performed by two-way analysis of variance (ANOVA). Pearson’s correlation was used to assess the association between two factors. $P \leq .05$ was considered statistically significant.

3 | RESULTS

3.1 | INPP1 is up-regulated in cervical cancer tissues

To identify the role of INPP1 in CC, RT-qPCR was used to examine the INPP1 expression levels in 20 pairs of CC tissues and their corresponding adjacent normal tissues. As shown in Figure 1A, the level of INPP1 mRNA was higher in the CC tissues than the levels in the normal tissues. The mean expression of INPP1 was increased by approximately fourfold (Figure 1B). Thus, INPP1 was up-regulated in CC.

FIGURE 1 High expression of INPP1 in CC tissues. A, Twenty pairs of tumour tissues and their adjacent normal tissues from 20 patients were assayed by qRT-PCR separately. The data were normalized to β-actin, and the INPP1 expression in normal tissues was arbitrarily defined as 100%. B, The mean expression of INPP1 in tumour tissues and adjacent normal tissues is shown. The INPP1 expression in normal tissues was arbitrarily defined as 100%, and the data are the mean ± SD of 20 samples (**: $P < .001$)
3.2 INPP1 promotes oncogenic activity in cervical cancer cells

To assess the role of INPP1 in CC, we constructed an INPP1 overexpression plasmid, pcDNA3-Flag/INPP1 (pINPP1) and a knockdown plasmid, pSilencer/shR-INPP1 (pshR-INPP1). First, we validated the effects of these plasmids at the mRNA and protein levels by RT-qPCR and Western blotting (Figure 2A). Next, to determine whether INPP1 influences the cell viability, MTT assays were used, and we suggested that INPP1 overexpression promoted cell viability, while INPP1 knockdown repressed the cell viability of HeLa and C33A cells (Figure 2B). Moreover, colony formation assays were performed to explore the effect of INPP1 on cell growth in HeLa and C33A cells. As shown in Figure 2C, compared with that in the control group, the colony formation rate was increased by approximately twofold in the pINPP1 group and was decreased by approximately 50% in the pshR-INPP1 group in HeLa and C33A cells, respectively. To determine whether INPP1 affects the mobility of CC cells, wound healing assays and transwell assays were used to examine the migration and invasion capacity. When INPP1 was overexpressed, the rates of migration and invasion were significantly increased by 1.5-fold and 1.8-fold, respectively, whereas they were significantly reduced by approximately 40% and 47%, respectively, when INPP1 was knocked down in HeLa cells (Figure 2D,E). Similar results were observed in C33A cells (Figure 2D,E). To determine the mechanisms behind the effects of INPP1 on cell mobility, epithelial-mesenchymal transition (EMT) markers were detected by Western blot. As expected, compared with the protein expression in the control groups, pINPP1 promoted vimentin protein expression and suppressed E-cadherin protein expression, and pshR-INPP1 suppressed vimentin protein expression.

**FIGURE 2** INPP1 functions as an oncogene in CC cells. A, HeLa and C33A cells were transfected with the overexpression plasmid pINPP1 or with the knockdown plasmid pshR-INPP1. Forty-eight hours after transfection, RT-qPCR (left) and Western blots (right) were used to examine the expression levels of INPP1. B, MTT assays were performed to examine the cell viability at 24, 48 or 72 h after transfection. C, Colony formation assays were used to examine the cell growth. HeLa and C33A cells were grown for 14 d, and the colony formation rate was calculated. D, Twenty-four hours after transfection, HeLa and C33A cells that were resuspended in 200 μL serum-free medium were seeded into inserts and were incubated for 60 h to examine the invasion abilities. After staining with crystal violet, the cells at the lower surface of the membrane were counted under a light microscope at five random fields. E, Wound healing assays were used to reveal the effect of INPP1 on the cell mobility. F, EMT-associated markers were assessed by Western blots (*: P < .05, **: P < .01, ***: P < .001)
expression and promoted E-cadherin protein expression (Figure 2F); this finding indicates that INPP1 was able to promote EMT in HeLa and C33A cells. We also obtained similar results in SiHa cells (Figure S1). Altogether, these results indicate that INPP1 may function as an oncogene in CC cells.

3.3 miR-27a targets and up-regulates INPP1 expression

To study the potential mechanisms underlying the dysregulation of INPP1, we investigated the effect of miRNA on INPP1 expression. Bioinformatics analysis (http://www.targetscan.org/vert_71/) was used to predict the candidate miRNAs that regulate INPP1. miR-27a was chosen for further studies because the INPP1 3′ UTR contains a miR-27a target site, and miR-27a has been reported to promote the malignancy of CC cells. RT-qPCR was performed to detect the expression level of miR-27a in the 20 pairs of tissues that had been used to measure the INPP1 mRNA levels. The results showed that miR-27a was up-regulated in these CC tissues compared with that in the adjacent normal cervical tissues (Figure 3A). The mean expression of miR-27a was increased by approximately 14-fold (Figure 3B). Furthermore, miR-27a also displayed a positive correlation with INPP1 (Figure 3C). To alter the miR-27a expression level, the miR-27a expression plasmid pri-miR-27a and the antisense oligonucleotide ASO-miR-27a were used to overexpress or block the expression of miR-27a in CC cells. After the transfection efficiency of pri-miR-27a and ASO-miR-27a was confirmed (Figure 3D), we examined the INPP1 mRNA and protein levels by RT-qPCR and

![FIGURE 3](https://example.com/figure3.png)
Knockdown of INPP1 abrogates the effects induced by miR-27a in CC cells. HeLa and C33A cells were cotransfected with pri-miR-27a or pshR-INPP1. An MTT assay (A), a colony formation assay (B), a transwell invasion assay (C) and a wound healing assay (D) were performed to analyse whether INPP1 knockdown could functionally rescue the miR-27a-induced phenotype. E, EMT-associated markers were measured by Western blots. (*: P < .05, **: P < .01, ***: P < .001)
Western blotting after the alteration of miR-27a levels in HeLa and C33A cells. As shown in Figure 3E,F, pri-miR-27a increased, while ASO-miR-27a decreased, the expression of INPP1. To further determine whether INPP1 was a direct target of miR-27a, the 3’ UTR of INPP1 that contained the miR-27a binding site or mutant site was cloned into a pmiRGLO Dual-Luciferase miRNA Target Expression Vector to generate the pmiRGLO-INPP1-3’ UTR/mut vector (Figure 3G). The luciferase activities were decreased when pmiRGLO-INPP1-3’ UTR and pri-miR-27a were cotransfected, whereas cotransfection with ASO-miR-27a caused an increase in the luciferase activity compared with that in the control group. In contrast, the mutation of the miR-27a binding site in the INPP1 3’ UTR abolished the effect of both pri-miR-27a and ASO-miR-27a on the luciferase activities in HeLa cells (Figure 3H). These results indicate that INPP1 is up-regulated by miR-27a at the post-transcriptional level in CC cells.

3.4 | Knockdown of INPP1 abolishes the malignant phenotype induced by miR-27a in cervical cancer cells

To verify that INPP1 indeed acts as the functional target of miR-27a, “rescue” experiments were performed. pri-miR-27a and pshR-INPP1 were cotransfected into HeLa, C33A and SiHa cells. As expected, the down-regulation of INPP1 abolished the promoting effects of miR-27a on cell viability (Figure 4A, Figure S2A), growth (Figure 4B, Figure S2B), invasion (Figure 4C, Figure S2C) and migration (Figure 4D, Figure S2D). Furthermore, the abnormal expression of EMT markers caused by miR-27a was also restored to normal levels after INPP1 knockdown (Figure 4E). Taken together, these data suggest that INPP1 is a functional target of miR-27a.

4 | DISCUSSION

Previous studies have reported that INPP1 is up-regulated in the vast majority of colorectal cancers. A recent report found that INPP1 is a highly expressed metabolic enzyme in aggressive ovarian and melanoma cancer cells and in primary human tumours, which drives cancer aggressiveness through regulating glycolytic metabolism and glucose-derived LPA synthesis. Cancer cells have a notable preference to utilize aerobic glycolysis, rather than mitochondrial oxidative phosphorylation, for glucose-dependent ATP production, which is thought to be the basis of tumour formation and growth.29 Thus, INPP1 attracted our attention.

In this study, we demonstrated that INPP1 was more highly expressed in CC tissues compared with that in adjacent normal tissues and that INPP1 facilitated the malignant behaviour of CC cells. Specifically, INPP1 overexpression significantly promoted cell viability, colony formation, migration and invasion, whereas shRNA-mediated INPP1 silencing inhibited these oncogenic features. In addition, Western blot assays indicated that the expression of EMT markers, such as E-cadherin and vimentin, was significantly modulated by INPP1. Thus, INPP1 may function as an oncogene in CC.

The dysregulation of miRNAs has been found to play key critical roles in up- or down-regulating the expression of its target gene30 and may be a marker of progression in CC.31 To determine the potential epigenetic mechanism of INPP1 up-regulation in CC, we investigated the regulation of miRNA on INPP1. First, bioinformatics was used to predict the miRNAs that target the 3’ UTR of INPP1, including miR-27a. A previous report suggested that the expression of miR-27a was significantly higher in cervical intraepithelial neoplasia (CIN) 2-3 compared to that in CIN1 (P = .023) and in squamous cell carcinoma (SCC) compared to that in CIN2-3 (P = .033).32,33 Many investigations have indicated that miR-27a is overexpressed in CC.25,34,35 The potential role of miR-27a is similar to that of INPP1. Due to previous reports that miRNAs can bind to the 3’ UTR of their target transcripts and enhance their expression,16,17 we explored whether miR-27a exerts its role through binding to the 3’ UTR of INPP1 to increase its expression. Thus, we first applied a luciferase reporter assay to determine whether miR-27a binds to the 3’ UTR of INPP1. The results indicated that miR-27a binds to the 3’ UTR of INPP1 to enhance the luciferase activity in the luciferase reporter assay. Next, using a gain-of-function and loss-of-function procedure, we uncovered that miR-27a enhanced the INPP1 expression at the mRNA and protein levels by Western blotting and RT-qPCR. In addition, RT-qPCR was used to examine the expression of miR-27a and INPP1 in 20 pairs of CC tissues and their corresponding adjacent normal tissues; the results showed the up-regulation of both miR-27a and INPP1, which supports our finding that miR-27a up-regulated INPP1 expression. However, its detailed mechanism needs to be understood. To determine whether INPP1 is the functional target gene of miR-27a, we designed a rescue experiment. The results verified that INPP1 decreased the ability of miR-27a to promote CC cells. Together, our data demonstrate that the miR-27a-mediated up-regulation of INPP1 may promote the tumorigenic activities of CC cells, which indicates that miRNAs target and up-regulate their target gene expression and may provide new insight into tumorigenesis in CC.

In summary, our findings indicate that both INPP1 and miR-27a are up-regulated in CC and that miR-27a binds to the 3’ UTR of INPP1 to increase the expression of INPP1. The overexpression of INPP1 promotes cell viability, colony formation, migration, invasion and EMT in CC cells and implies its potential role as a biomarker in CC.

ACKNOWLEDGEMENTS

This work was supported by the key project of the Committee of Health of Tianjin (No: 16KJ111).

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

Pu Li conceived and designed the experiments; Pu Li and Qiaoge Zhang performed and analysed most of the experiments; Hua Tang...
contributed to the analyses of data; Pu Li and Qiaoge Zhang wrote the manuscript.

ORCID

Hua Tang https://orcid.org/0000-0003-3074-3561

REFERENCES

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65:87-108.
2. Marquina G, Manzano A, Casado A. Targeted agents in cervical cancer: beyond bevacizumab. Curr Oncol Rep. 2018;20:40.
3. Xu HH, Wang K, Feng XJ, et al. Prevalence of human papillomavirus genotypes and relative risk of cervical cancer in China: a systematic review and meta-analysis. Oncotarget. 2018;9:15386-15397.
4. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA: Cancer J Clin. 2016;66:115-132.
5. Kumar L, Harish P, Malik PS, et al. Chemotherapy and targeted therapy in the management of cervical cancer. Curr Probl Cancer. 2018;42:120-128.
6. Inhorn RC, Majerus PW. Inositol polyphosphate 1-phosphatase from calf brain. Purification and inhibition by Li+, Ca2+, and Mn2+. J Biol Chem. 1987;262:15946-15952.
7. Amare AT, Schubert KO, Baune BT. Pharmacogenomics in the treatment of mood disorders: strategies and opportunities for personalized psychiatry. EPMA J. 2017;8:211-227.
8. Li SR, Gyselman VG, Lalude O, et al. Transcription of the inositol polyphosphate 1-phosphatase gene (INPP1) is upregulated in human colorectal cancer. Mol Carcinog. 2000;27:322-329.
9. Benjamin DI, Louie SM, Mulvihill MM, et al. Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. ACS Chem Biol. 2014;9:1340-1350.
10. Fressigne L, Simard MJ. [Biogenesis of small non-coding RNAs in animals]. Med Sci. 2018;34:137-144.
11. Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673-677.
12. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
13. Zhang LY, Liu M, Li X, et al. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem. 2013;288:4035-4047.
14. Song G, Wang R, Guo J, et al. miR-346 and miR-138 competitively regulate hTERT in GRSF1- and AGO2-dependent manners, respectively. Sci Rep. 2015;5:15793.
15. Guo J, Lv J, Liu M, et al. miR-346 up-regulates argonaute 2 (AGO2) protein expression to augment the activity of other microRNAs (miRNAs) and contributes to cervical cancer cell malignancy. J Biol Chem. 2015;290:30342-30350.
16. Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014;20:10432-10439.
17. Granados Lopez AJ, Lopez JA. Multistep model of cervical cancer: participation of miRNAs and coding genes. Int J Mol Sci. 2014;15:15700-15733.
18. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE. 2008;3:e2557.
19. Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5:1122-1143.
20. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discovery. 2014;13:622-638.
21. Luo W, Zhang D, Ma S, et al. miR-27a is highly expressed in H1650 cancer stem cells and regulates proliferation, migration, and invasion. J Cancer Res Ther. 2018;14:S1004-S1011.
22. Jiang G, Shi W, Fang H, et al. miR27a promotes human breast cancer cell migration by inducing EMT in a FBXW7-dependent manner. Mol Med Rep. 2018;18:5417-5426.
23. Gao W, Hong Z, Huang H, et al. miR-27a in serum as Biomarker for prostate cancer detection and promotes cell proliferation by targeting Sprouty2. Oncol Lett. 2018;16:5291-5298.
24. Li W, Yu ZX, Ma BF. The increase of miR-27a affects the role of cisplatin on proliferation and migration capacities of liver cancer cells. Eur Rev Med Pharmacol Sci. 2018;22:5490-5498.
25. Sun Y, Yang X, Liu M, et al. B4AGALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells. Cancer Lett. 2016;375:284-292.
26. Chen C, Ridzdan DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33:e179.
27. Long MJ, Wu FX, Li P, et al. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012;324:186-196.
28. Wan HY, Li QQ, Zhang Y, et al. MiR-124 represses vascuogenic mimicry and cell motility by targeting amotl1 in cervical cancer cells. Cancer Lett. 2014;355:148-158.
29. Hu ZY, Xiao L, Bode AM, et al. Glycolytic genes in cancer cells are more than glucose metabolic regulators. J Mol Med. 2014;92:837-845.
30. Diaz-Gonzalez Sdel M, Deas J, Benitez-Bojiseanou O, et al. Utility of microRNAs and siRNAs in cervical carcinogenesis. Biomed Res Int. 2015;2015:374924.
31. Pardini B, De Maria D, Francavilla A, et al. MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC Cancer. 2018;18:696.
32. Gocze K, Gombos K, Kovacs K, et al. MicroRNA expressions in HPV-induced cervical dysplasia and cancer. Anticancer Res. 2015;35:523-530.
33. Wilting SM, Snijders PJ, Verlaat W, et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene. 2013;32:106-116.
34. Pereira PM, Marques JP, Soares AR, et al. MicroRNA expression variability in human cervical tissues. PLoS ONE. 2010;5:e11780.
35. Wang X, Wang HK, Li Y, et al. microRNAs are biomarkers of oncogenic human papillomavirus infections. Proc Natl Acad Sci USA. 2014;111:4262-4267.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Li P, Zhang Q, Tang H. INPP1 up-regulation by miR-27a contributes to the growth, migration and invasion of human cervical cancer. J Cell Mol Med. 2019;23:7709-7716. https://doi.org/10.1111/jcmm.14644